Fulcrum Therapeutics, Inc.
FULC
$7.63
-$0.02-0.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 80.00M | 80.00M | 80.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 80.00M | 80.00M | 80.87M |
| Cost of Revenue | 52.40M | 52.74M | 57.02M | 63.39M | 70.67M |
| Gross Profit | -52.40M | -52.74M | 22.98M | 16.61M | 10.20M |
| SG&A Expenses | 29.11M | 29.97M | 33.39M | 36.45M | 38.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.51M | 82.71M | 90.40M | 99.83M | 109.27M |
| Operating Income | -81.51M | -82.71M | -10.40M | -19.83M | -28.40M |
| Income Before Tax | -71.11M | -73.22M | -510.00K | -9.73M | -17.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.11 | -73.22 | -0.51 | -9.73 | -17.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.11M | -73.22M | -510.00K | -9.73M | -17.91M |
| EBIT | -81.51M | -82.71M | -10.40M | -19.83M | -28.40M |
| EBITDA | -80.09M | -81.28M | -8.94M | -18.24M | -26.67M |
| EPS Basic | -1.18 | -1.21 | -0.05 | -0.20 | -0.29 |
| Normalized Basic EPS | -0.74 | -0.74 | -0.01 | -0.10 | -0.16 |
| EPS Diluted | -1.19 | -1.22 | -0.07 | -0.22 | -0.31 |
| Normalized Diluted EPS | -0.74 | -0.74 | -0.02 | -0.11 | -0.17 |
| Average Basic Shares Outstanding | 241.57M | 241.39M | 241.05M | 240.55M | 248.47M |
| Average Diluted Shares Outstanding | 241.57M | 241.39M | 242.43M | 241.93M | 249.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |